title: Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty.
abstract: BACKGROUND
  We hypothesized that transfection of the gene for human hepatocyte growth factor (hHGF) combined with cellular cardiomyoplasty might regenerate the impaired myocardium.
  
  
  RESULTS
  We used a ligation model of proximal left anterior descending coronary artery (LAD) of Lewis rats. Two weeks after LAD ligation, 3 different treatments were conducted: (1) neonatal rat cardiomyocytes group (10(6) cells, T group, n=11), (2) HVJ-liposomes bearing the hHGF gene group (H group, n=10), and (3) combined (T-H group, n=10). The injection site was the scar area of myocardial infarction. For control, culture medium was injected (C group, n=13). Echocardiography demonstrated that cardiac performance was significantly ameliorated in the T-H group 4 and 8 weeks after injection. Contrast echocardiography also showed a marked increase in myocardial perfusion in the T-H group but not in the other groups. In the T-H group, neovascularization and a marked reduction of fibrosis were observed histologically. In an immunohistochemical study, strong staining for beta(1)-integrin, alpha-, and beta-dystroglycan were found principally in the basement membrane of myocytes in the T-H group 8 weeks after transplantation, although there was weak immunoreactivity in the T group.
  
  
  CONCLUSIONS
  hHGF gene transfection enhanced the cellular cardiomyoplasty possibly by stimulating angiogenesis, restoring the impaired ECM, and promoting the integration of the dissociated grafted myocytes. The combined effects might have lead to the improved cardiac performance. Thus, combined therapy may be a promising strategy for the treatment of heart failure caused by myocardial infarction.
authors.affiliation: Division of Cardiovascular Surgery, Department of Surgery E1, School of Allied Health Science, Faculty of Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Shigeru
authors.initials: S
authors.lastname: Miyagawa
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sawa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Taketani
authors.forename: Naomasa
authors.initials: N
authors.lastname: Kawaguchi
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Nakamura
authors.forename: Nariaki
authors.initials: N
authors.lastname: Matsuura
authors.forename: Hikaru
authors.initials: H
authors.lastname: Matsuda
mesh_terms: D000818:Animals; D018421:Cardiomyoplasty / Q000379:methods*; D017690:Cell Transplantation / Q000379:methods; D002478:Cells, Cultured; D002908:Chronic Disease; D003326:Coronary Circulation / Q000187:drug effects; D004195:Disease Models, Animal; D004452:Echocardiography; D015316:Genetic Therapy / Q000379:methods; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology; D006333:Heart Failure / Q000209:etiology / Q000628:therapy*; D006334:Heart Function Tests / Q000187:drug effects; D017228:Hepatocyte Growth Factor / Q000235:genetics / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000628:therapy; D009206:Myocardium / Q000166:cytology; D051381:Rats; D011917:Rats, Inbred Lew; D012038:Regeneration / Q000187:drug effects / Q000235:genetics; D013318:Stroke Volume / Q000187:drug effects; D014162:Transfection; D016896:Treatment Outcome
chemical_list: D017228:Hepatocyte Growth Factor